Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function
Attaya Suvannasankha(Indiana University Health), Maria R. Baer(University of Maryland, Baltimore), Hans Minderman(Roswell Park Comprehensive Cancer Center), Kieran L. O’Loughlin(Roswell Park Comprehensive Cancer Center), Takeo Nakanishi(Takasaki University of Health and Welfare), D D Ross(University of Maryland, Baltimore), William R. Greco(Roswell Park Comprehensive Cancer Center)
Cited by 71
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764